The role of cell free DNA and liquid biopsies in haematological conditions

Abstract

Cell free nucleic acids (CFNAs) are nucleic acids released from cells that circulate within bodily fluids. Recent advances in molecular techniques have led the ability to interrogate CFNAs in a clinically meaningful way, for example the identification and assessment of foetal CFNAs in maternal blood, allowing minimally invasive testing for foetal genetic abnormalities. The majority of CFNAs arise from haemopoietic cells, making it a particularly rich source of genetic information in haematological conditions. Furthermore, the innate genetic heterogeneity of haematological malignancies, as epitomised by multiple myeloma, lend itself well to “liquid biopsies”. This approach promises to provide a more wholistic assessment of whole disease genetics, especially when contrasted against the current gold-standard of single site tissue biopsies. This review briefly summarises the definitions and physiology of CFNAs, both cell free DNA (cfDNA) and extracellular RNA (exRNA), before exploring the literature surrounding the current and future roles of cfDNA in the haematological malignancies and patient care.

Keywords

cfDNA / liquid biopsy / haematology / myeloma / lymphoma / leukaemia

References

[1] Mandel P.Les acides nucléiques du plasma sanguin chez l’homme..C R Seances Soc Biol Fil1948;142:241-3

[2] Vasioukhin V,Maurice P,Lederrey C.Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia..Br J Haematol1994;86:774-9

[3] Sorenson GD,Valone FH,Bzik DJ.Soluble normal and mutated DNA sequences from single-copy genes in human blood..Cancer Epidemiol Biomarkers Prev1994;3:67-71

[4] Lui YYN,Chiu RWK,Lam CWK.Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation..Clin Chem2002;48:421-7

[5] Snyder MW,Hill AJ,Shendure J.Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin..Cell2016;164:57-68 PMCID:PMC4715266

[6] Peters DL.Origin, translocation and destination of extracellular occurring DNA--a new paradigm in genetic behaviour..Clin Chim Acta2011;412:806-11

[7] Kahlert C,Protopopov A,Seth S.Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer..J Biol Chem2014;289:3869-75 PMCID:PMC3924256

[8] Jeppesen DK,Franklin JL,Zhang Q.Reassessment of exosome composition..Cell2019;177:428-45.e18 PMCID:PMC6664447

[9] Valadi H,Bossios A,Lee JJ.Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells..Nat Cell Biol2007;9:654-9

[10] Fournié GJ,Laval F,Pourrat JP.Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours..Cancer Lett1995;91:221-7

[11] Jahr S,Englisch S,Fackelmayer FO.DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells..Cancer Res2001;61:1659-65

[12] Choi JJ,Pisetsky DS.The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells..Immunology2005;115:55-62 PMCID:PMC1782131

[13] Stroun M,Lederrey C,Anker P.About the possible origin and mechanism of circulating DNA apoptosis and active DNA release..Clin Chim Acta2001;313:139-42

[14] Leon SA,Sklaroff DM.Free DNA in the serum of cancer patients and the effect of therapy..Cancer Res1977;37:646-50

[15] Fleischhacker M.Circulating nucleic acids (CNAs) and cancer--a survey..Biochim Biophys Acta2007;1775:181-232

[16] Sunami E,Nguyen SL,Hoon DSB.Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer..Ann N Y Acad Sci2008;1137:171-4

[17] Snyder TM,Valantine HA.Universal noninvasive detection of solid organ transplant rejection..Proc Natl Acad Sci U S A2011;108:6229-34 PMCID:PMC3076856

[18] Wan JCM,Garcia-Corbacho J,Brenton JD.Liquid biopsies come of age: towards implementation of circulating tumour DNA..Nat Rev Cancer2017;17:223-38

[19] De Vlaminck I,Kertesz M,Kowarsky M.Noninvasive monitoring of infection and rejection after lung transplantation..Proc Natl Acad Sci U S A2015;112:13336-41 PMCID:PMC4629384

[20] Chiu RWK,Gao Y,Zheng W.Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma..Proc Natl Acad Sci U S A2008;105:20458-63 PMCID:PMC2600580

[21] Underhill HR,Hellwig S,Daza R.Fragment length of circulating tumor DNA..PLoS Genet2016;12:e1006162 PMCID:PMC4948782

[22] Fan HC,Chitkara U,Quake SR.Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood..Proc Natl Acad Sci U S A2008;105:16266-71 PMCID:PMC2562413

[23] Cooper MD.The early history of B cells..Nat Rev Immunol2015;15:191-7

[24] Frickhofen N,Sandherr M,Bangerter M.Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with b-cell neoplasia..Blood1997;90:4953-60

[25] He J,Jiao Y,Ambinder RF.IgH gene rearrangements as plasma biomarkers in Non- Hodgkin’s lymphoma patients..Oncotarget2011;2:178-85 PMCID:PMC3260819

[26] Wu FT,Xu W.Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma..Ann Hematol2018;98:255-69

[27] Deligezer U,Erten N.Frequent copresence of methylated DNA and fragmented nucleosomal DNA in plasma of lymphoma patients..Clin Chim Acta2003;335:89-94

[28] Shi H,Duff DJ,Chitima-Matsiga R.Discovery of novel epigenetic markers in non-Hodgkin’s lymphoma..Carcinogenesis2007;28:60-70

[29] Kammesheidt A,Lim SW.Mutation detection using plasma circulating tumor DNA (ctDNA) in a cohort of asymptomatic adults at increased risk for cancer..Int J Mol Epidemiol Genet2018;9:1-12 PMCID:PMC5840340

[30] Kurtz DM,Bratman SV,Liu CL.Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing..Blood2015;125:3679-87 PMCID:PMC4463733

[31] Mithraprabhu S.Analysis of circulating tumor DNA..Methods Mol Biol2018;1792:129-45

[32] Kubaczkova V,Sedlarikova L,Sevcikova S.Cell-free DNA - Minimally invasive marker of hematological malignancies..Eur J Haematol2017;99:291-9

[33] Perdigones N.Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis..Pharmacol Ther2017;174:22-6

[34] Bohers E,Dubois S,Maingonnat C.Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis..Haematologica2015;100:e280-4 PMCID:PMC4486242

[35] Wu YL,Hu CP,Lu S.EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6..Br J Cancer2017;116:175-85 PMCID:PMC5243999

[36] Rasche L,Stephens OW,Tytarenko R.Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing..Nat Commun2017;8:268 PMCID:PMC5559527

[37] Mithraprabhu S,Chen M,Spencer A.Circulating tumour DNA analysis for tumour genome characterisation and monitoring disease burden in extramedullary multiple myeloma..Int J Mol Sci2018;19: PMCID:PMC6073672

[38] Mithraprabhu S,Khong T,Bergin K.Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients..Leukemia2019;33:2022-33

[39] Dawson MA,Spencer A.Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains..Haematologica2007;92:143-4

[40] Usmani SZ,Mitchell A,Nair B.Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents..Haematologica2012;97:1761-7 PMCID:PMC3487453

[41] Oberle A,Voigtlaender M,Radloff J.Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA..Haematologica2017;102:1105-11 PMCID:PMC5451343

[42] Mithraprabhu S,Ramachandran M,Klarica D.DNA-repair gene mutations are highly prevalent in circulating tumour DNA from multiple myeloma patients..Cancers (Basel)2019;11: PMCID:PMC6678219

[43] Tilly H,Vitolo U,Meignan M.Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2015;26:v116-25

[44] De Mattos-Arruda L,Ng CKY,Martínez-Ricarte F.Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma..Nat Commun2015;6:8839 PMCID:PMC5426516

[45] Wang Y,Zhang M,Kinde I.Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord..Proc Natl Acad Sci U S A2015;112:9704-9 PMCID:PMC4534284

[46] Fontanilles M,Bohers É,Dubois S.Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma..Oncotarget2017;8:48157-68 PMCID:PMC5564634

[47] Newman AM,To J,Eclov NC.An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage..Nat Med2014;20:548-54 PMCID:PMC4016134

[48] Scherer F,Newman AM,Craig AF.Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA..Sci Transl Med2016;8:ra155 PMCID:PMC5490494

[49] Rossi D,Spaccarotella E,Zanni M.Diffuse large B-cell lymphoma genotyping on the liquid biopsy..Blood2017;129:1947-57

[50] Assi RE,Ma W,Takahashi K.Comparison of somatic mutations profiles from next-generation sequencing (NGS) of cell-free DNA (cfDNA) versus bone marrow (BM) in acute myeloid leukemia (AML)..J Clin Oncol2018;36:7051

[51] Murtaza M,Tsui DW,Forshew T.Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA..Nature2013;497:108-12

[52] Wilson WH,Schmitz R,Pittaluga S.Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma..Nat Med2015;21:922-6

[53] Camus V,Bohers E,Mareschal S.Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma..Leuk Lymphoma2016;57:2171-9

[54] Herrera AF,Kong KA,Sun H.Next-generation sequencing-based detection of circulating tumour DNA after allogeneic stem cell transplantation for lymphoma..Br J Haematol2016;175:841-50 PMCID:PMC5123935

[55] Barault L,Bleeker FE,Falcomatà C.Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer..Ann Oncol2015;26:1994-9

[56] Bedin C,Del Bianco P,Nitti D.Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients..Int J Cancer2017;140:1888-98

[57] Kristensen LS,Kristensen SS,Harsløf LB.Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma..Clin Epigenetics2016;8:95 PMCID:PMC5015248

[58] Wedge E,Garde C,Tholstrup D.Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma..Am J Hematol2017;92:689-94

[59] Roschewski M,Pittaluga S,Pepin F.Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study..Lancet Oncol2015;16:541-9 PMCID:PMC4460610

[60] Assouline SE,Yu S,Chong L.Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma..Blood2016;128:185-94 PMCID:PMC4972610

[61] Camus V,Mareschal S,Sarafan-Vasseur N.Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma..Haematologica2016;101:1094-101 PMCID:PMC5060026

[62] Suehara Y,Hattori K,Itoh T.Liquid biopsy for the identification of intravascular large B-cell lymphoma..Haematologica2018;103:e241-e4 PMCID:PMC6058794

[63] Mussolin L,Pillon M,Farruggia P.Plasma cell-free DNA in paediatric lymphomas..J Cancer2013;4:323-9 PMCID:PMC3654488

[64] Sakata-Yanagimoto M,Komori D,Hattori K.Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma..Ann Hematol2017;96:1471-75

[65] Aljurf M,Alseraihy A,Ayas M.Chimerism analysis of cell-free DNA in patients treated with hematopoietic stem cell transplantation may predict early relapse in patients with hematologic malignancies..Biotechnol Res Int2016;8589270 PMCID:PMC4781938

[66] Nakamura S,Shimizu E,Kondoh K.Personalized circulating tumor DNA predicts relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome..Blood2017;133:2682-95

[67] Swerdlow SH,Harris NL.WHO classification of tumours of haematopoietic and lymphoid tissues..(IARC Who Classification of Tum, 2017).

[68] Yeh P,Ftouni S,Sinha D.Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes..Blood2017;129:1685-90

[69] Albitar A,Ma W,Funari V.Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA as compared with BM..Leukemia2018;32:227-29 PMCID:PMC5770590